Citi analyst Joanne Wuensch raised the firm’s price target on iRhythm (IRTC) to $205 from $183 and keeps a Buy rating on the shares. The firm is cautious on medical technology entering the Q3 earnings season. Citi believes the outcome of the Section 232 investigation into medical equipment and devices will take time.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- iRhythm price target raised to $193 from $170 at Canaccord
- CoreWeave upgraded, Lululemon downgraded: Wall Street’s top analyst calls
- iRhythm initiated with an In Line at Evercore ISI
- Irhythm Technologies: Strategic Market Expansion and Clinical Efficacy Drive Buy Rating
- iRhythm Technologies: Strategic Partnerships and Growth Potential Drive Buy Rating